Home
Drugs
Bevacizumab
Clinical Trials

Clinical Trials Related to Bevacizumab

Related studies linked through entity extraction aliases.

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE3

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE1

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Status: RECRUITING
Phase: PHASE3

SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

Status: NOT_YET_RECRUITING
Phase: PHASE3

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Status: NOT_YET_RECRUITING
Phase: PHASE1

SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE3

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

Status: RECRUITING
Phase: PHASE2

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Status: NOT_YET_RECRUITING
Phase: PHASE2

JS212 Combination Therapies in Metastatic Colorectal Cancer

Status: RECRUITING
Phase: PHASE2

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE1

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Status: RECRUITING
Phase: PHASE2/PHASE3

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Status: RECRUITING
Phase: PHASE3

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Status: RECRUITING
Phase: PHASE1

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Status: RECRUITING
Phase: NA

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Status: NOT_YET_RECRUITING
Phase: PHASE2